About
Microbiome combination drug development
Areas of Focus
Categories
Microbiome
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
5
As Collaborator
5
Total Enrollment
9,904
By Phase
PHASE1/PHASE2: 3NA: 3PHASE2: 1
By Status
RECRUITING: 5ACTIVE_NOT_RECRUITING: 2SUSPENDED: 1ENROLLING_BY_INVITATION: 1TERMINATED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07172802Lead Sponsor
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
PHASE1/PHASE2Recruiting
76 participants
Started: Apr 22, 2025 · Completed: Sep 30, 2027
NCT06252233Collaborator
Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer
NARecruiting
220 participants
Started: Feb 15, 2024 · Completed: Aug 15, 2025
NCT06182085Lead Sponsor
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
PHASE2Active, not recruiting
304 participants
Started: Dec 1, 2023 · Completed: Apr 30, 2026
NCT05824975Lead Sponsor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
PHASE1/PHASE2Recruiting
358 participants
Started: May 30, 2023 · Completed: Apr 24, 2027
NCT05565170Collaborator
Digitally Supported Lifestyle Programme to Promote Brain Health Among Older Adults
NAActive, not recruiting
156 participants
Started: Jan 30, 2023 · Completed: Mar 31, 2025
Locations (1)
Headquarters
Seoul, Korea
Map
Loading map...